PRAC publishes October signal recommendations: what PV teams can act on before the detail is read

What happened

On 26 October 2026 the EMA published the PRAC recommendations on safety signals adopted at the committee's plenary of 28 September to 1 October 2026. The document is on the EMA website as a PDF titled for signals adopted at that meeting.

The detail was not available at the time of writing. This article therefore does not say which active substances were covered, what signals were assessed or what product information changes were recommended. Those points are not yet known to us, and readers should check the published PDF directly.

The publication still marks the start of a working cycle for PV teams, whatever the content turns out to be.

Why it matters even before you read the detail

A PRAC signal recommendation is the committee's view on whether a possible new or changed risk linked to a medicine needs action. In general terms, the outcome may be a change to the product information, a request for further data, or no action beyond routine monitoring. Recommendations are normally followed by the relevant EU decision-making route, depending on whether the product is centrally or nationally authorised. Marketing authorisation holders are then expected to submit variations within set timelines.

For QPPVs the practical risk is lag. A recommendation can sit in a long PDF while a product on your portfolio is named in it. Screening the document promptly, and logging the result, is the simplest way to show that your pharmacovigilance system picked up the publication and responded.

Regulatory context from the same week

Several other records from the same days show how signal outputs fit into the wider EU safety picture.

On 28 October the EMA published CMDh conclusions and an implementation timetable for valproate product information changes, under reference EMA/PASS/0000287665. The document sets out scientific conclusions, grounds for variation, amended Product Information and a timetable. The records do not link it to the PRAC signal recommendations, and we do not suggest a link. It is a reminder that a safety outcome becomes a compliance task once the amended text and timetable are fixed. Holders of valproate medicines should read the document for their own obligations.

In Germany, the Paul-Ehrlich-Institut and BfArM published issue 3/2026 of their joint quarterly drug safety bulletin. It features a reassessment of the live vaccine Ixchiq, risks of silicone oil droplets with intravitreal therapies, and OTC pharmacovigilance. The records give no detail on those articles. Even so, the topics show where national authorities are directing attention: a vaccine under review, a product-quality-related risk in ophthalmic injections, and the safety monitoring of non-prescription medicines.

The PEI is also backing #MedSafetyWeek 2026, running 2–8 November. It stresses that spontaneous reports of suspected adverse reactions remain central to post-authorisation safety monitoring. That matters because spontaneous reports are a main source of the signals PRAC later evaluates.

Who is affected

Marketing authorisation holders with products named in the recommendations are directly affected, as are the QPPVs and local safety officers responsible for them. Holders of nationally authorised products should also follow national and CMDh-related communications, since implementation often runs through those channels.

Wider vigilance work is touched by the week's other records. A Löwenstein field safety notice for LUISA, TIVAN, LS and Life One ventilators, published by the Dutch inspectorate IGJ, cites a possible communication failure of the battery. FDA has issued an early alert on B. Braun Streamline Bloodline Sets for Dialog+, after a missing solvent step left some dialyzer connectors inadequately bonded in three lots. These are device matters, not medicinal product signals. Teams handling combination products or device-linked adverse event reports may still need to check for overlap.

On the biovigilance side, BASG reports that ECDC has notified additional West Nile Virus cases in Serbia. The case numbers and regions were not available in the record. BASG notes the relevance to blood and substance-of-human-origin safety, for instance donor deferral for travellers returning from affected areas. The EU Health Security Committee also met on 27 and 28 October and adopted opinions on mosquito-borne diseases and healthcare infrastructure resilience.

What to watch

First, the content of the PRAC document: which substances, which signal types, and whether any recommendation sets deadlines for variations or data submissions.

Second, follow-on steps. For any product affected, watch for the EMA or national route that turns a recommendation into amended product information, and for the timetable attached to it.

Third, the reporting push around #MedSafetyWeek from 2 to 8 November. Teams may see more spontaneous reports in that period, which can affect case intake and processing.

Finally, the German bulletin's Ixchiq reassessment and silicone oil droplet features should be read in full by those with relevant products. The records give no conclusions on either.